Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase – a report from the Swedish CML Group

• Published in: British journal of haematology 2002-09, Vol.118 (4), p.1048-1054
• Main Authors: Axdorph, Ulla, Stenke, Leif, Grimfors, Gunnar, Carneskog, Jan, Hansen, Jan, Linder, Olle, Ljungman, Per, Löfvenberg, Eva, Malm, Claes, Simonsson, Bengt, Turesson, Ingemar, Vilén, Lars, Udén, Anne‐Marie, Björkholm, Magnus
• Format: Article
• Language: English
• Subjects: accelerated/blastic phase; Adolescent; Adult; Aged; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Blast Crisis; Chemotherapy; Clinical Medicine; CML; Combined Modality Therapy; Cytarabine - administration & dosage; Etoposide - administration & dosage; Female; Hematologi; Hematology; Humans; Klinisk medicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - surgery; Male; Medical and Health Sciences; Medical sciences; MEDICIN; Medicin och hälsovetenskap; MEDICINE; Middle Aged; Mitoxantrone - administration & dosage; Pharmacology. Drug treatments; Prognosis; Remission Induction; Statistics, Nonparametric; Stem Cell Transplantation; Survival Rate
• ISSN: 0007-1048; 1365-2141; 1365-2141
• DOI: 10.1046/j.1365-2141.2002.03765.x

In attempting to restore the chronic phase (CP) of chronic myelogenous leukaemia (CML), the Swedish CML group utilized an intensive chemotherapy protocol for 83 patients (aged 16–79 years) in accelerated (AP, n = 22) or blastic phase (BC, n = 61). Most patients received a combination of mitoxantrone (12 mg/m2/d) and etoposide (100 mg/m2/d) together with cytosine arabinoside (1 g/m2 b.i.d) for 4 d. Overall, 39 patients (47%) achieved a second CP (CP2)/partial remission (PR). Responding patients